290 related articles for article (PubMed ID: 36969239)
1. A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.
Carter B; Huang P; Liu G; Liang Y; Lin PJC; Peng BH; McKay LGA; Dimitrakakis A; Hsu J; Tat V; Saenkham-Huntsinger P; Chen J; Kaseke C; Gaiha GD; Xu Q; Griffiths A; Tam YK; Tseng CK; Gifford DK
Front Immunol; 2023; 14():1135815. PubMed ID: 36969239
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
3. Cross-protection induced by highly conserved human B, CD4
Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzer B; Shaik AM; Chilukuri A; Edwards RA; Singer M; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
Front Immunol; 2024; 15():1328905. PubMed ID: 38318166
[TBL] [Abstract][Full Text] [Related]
4. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
Takagi A; Matsui M
Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
[TBL] [Abstract][Full Text] [Related]
5. mRNA-LNP vaccine-induced CD8
Montoya B; Melo-Silva CR; Tang L; Kafle S; Lidskiy P; Bajusz C; Vadovics M; Muramatsu H; Abraham E; Lipinszki Z; Chatterjee D; Scher G; Benitez J; Sung MMH; Tam YK; Catanzaro NJ; Schäfer A; Andino R; Baric RS; Martinez DR; Pardi N; Sigal LJ
Mol Ther; 2024 Jun; 32(6):1790-1804. PubMed ID: 38605519
[TBL] [Abstract][Full Text] [Related]
6. Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine.
Qin J; Jeon JH; Xu J; Langston LK; Marasini R; Mou S; Montoya B; Melo-Silva CR; Jeon HJ; Zhu T; Sigal LJ; Xu R; Zhu H
Front Immunol; 2023; 14():1126392. PubMed ID: 37033973
[TBL] [Abstract][Full Text] [Related]
7. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants.
Tai W; Feng S; Chai B; Lu S; Zhao G; Chen D; Yu W; Ren L; Shi H; Lu J; Cai Z; Pang M; Tan X; Wang P; Lin J; Sun Q; Peng X; Cheng G
Nat Commun; 2023 May; 14(1):2962. PubMed ID: 37221158
[TBL] [Abstract][Full Text] [Related]
8. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
10. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
[TBL] [Abstract][Full Text] [Related]
12. Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.
Abdelaziz MO; Raftery MJ; Weihs J; Bielawski O; Edel R; Köppke J; Vladimirova D; Adler JM; Firsching T; Voß A; Gruber AD; Hummel LV; Fernandez Munoz I; Müller-Marquardt F; Willimsky G; Elleboudy NS; Trimpert J; Schönrich G
Front Immunol; 2023; 14():1166765. PubMed ID: 37520530
[TBL] [Abstract][Full Text] [Related]
13. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
14. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
15. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
Front Immunol; 2022; 13():942192. PubMed ID: 36275696
[TBL] [Abstract][Full Text] [Related]
16. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
Prakash S; Dhanushkodi NR; Singer M; Quadiri A; Zayou L; Vahed H; Coulon PG; Ibraim IC; Tafoya C; Hitchcock L; Landucci G; Forthal DN; El Babsiri A; Tifrea DF; Figueroa CJ; Nesburn AB; Kuppermann BD; Gil D; Jones TM; Ulmer JB; BenMohamed L
bioRxiv; 2024 Feb; ():. PubMed ID: 38405942
[TBL] [Abstract][Full Text] [Related]
17. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
Corleis B; Hoffmann D; Rauch S; Fricke C; Roth N; Gergen J; Kovacikova K; Schlottau K; Halwe NJ; Ulrich L; Schön J; Wernike K; Widera M; Ciesek S; Mueller SO; Mettenleiter TC; Maione D; Petsch B; Beer M; Dorhoi A
Nat Commun; 2023 Feb; 14(1):816. PubMed ID: 36781853
[TBL] [Abstract][Full Text] [Related]
19. Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy.
Sankaranarayanan S; Mohkhedkar M; Janakiraman V
Biochim Biophys Acta Mol Basis Dis; 2022 Sep; 1868(9):166432. PubMed ID: 35568352
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
